Substantiated regulatory routes exist for specific ingredients, such as the EFSA-authorised glucomannan weight-management and oat beta-glucan cholesterol claims under their defined conditions of use [6]
Mean weight decreased to 97.41 9.38 kg in the IGB only group and to 88.00 8.64 kg in the IGB + semaglutide group ( p = 0.002)
Drug Resist Updat 32:2346
Month 1: 0.5 mg, once daily Month 2: 1 mg, once daily Month 3: 1.5 mg, once daily Month 4: 2 mg, once daily Month 5 and beyond (maintenance): 2.5 mg, once daily Medication is prescribed only after consultation with a licensed provider to determine appropriateness
Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial Frias JP, Deenadayalan S, Erichsen L, et al